 |
|
A new tool against brain disease
August 21, 2006University of Utah researchers isolated an unusual nerve toxin in an ocean-dwelling snail, and say its ability to glom onto the brain's nicotine receptors may be useful for designing new drugs to treat a variety of psychiatric and brain diseases.
"We discovered a new toxin from a venomous cone snail that may enable scientists to more effectively develop medications for a wide range of nervous system disorders including Parkinson's disease, Alzheimer's disease, depression, nicotine addiction and perhaps even schizophrenia," says J. Michael McIntosh.
Discovery of the new cone snail toxin will be published Friday, Aug. 25 in The Journal of Biological Chemistry by a team led by McIntosh, a University of Utah research professor of biology, professor and research director of psychiatry, member of the Center for Peptide Neuropharmacology and member of The Brain Institute.
McIntosh is the same University of Utah researcher who - as an incoming freshman student in 1979 - discovered another "conotoxin" that was developed into Prialt, a drug injected into fluid surrounding the spinal cord to treat severe pain due to cancer, AIDS, injury, failed back surgery and certain nervous system disorders. Prialt was approved in late 2004 in the United States and was introduced in Europe last month.
Prialt, sold by Ireland's Elan Pharmaceuticals, took roughly 25 years to reach market after its discovery in venom from the fish-eating cone snail Conus magus or magician's cone. McIntosh says he expects it will take 10 to 20 years to develop new medications based on what is learned from the new toxin - named alpha conotoxin OmIA (oh-em-one-ay) - isolated from a cone snail species named Conus omaria, which lives in the Pacific and Indian oceans and eats other snails. It ranges from 1¾ to 3½ inches long.
McIntosh discovered and analyzed the new toxin with help from University of Utah cone snail research pioneer Baldomero "Toto" Olivera, who is a distinguished professor of biology, and lab technicians Sean B. Christensen and Cheryl Dowell.
Other coauthors of the study are Palmer Taylor, professor and dean of pharmacology at the University of California, San Diego, and his associates - Todd Talley, Igor Tsigelny and Kwok-Yiu Ho - as well as Kyou-Hoon Han at the Korea Research Institute of Bioscience and Biotechnology.
Diseases that Might Benefit from the New Snail Toxin
McIntosh says the OmIA toxin will be useful in designing new medicines because it fits like a key into certain lock-like "nicotinic acetylcholine receptors" found on nerve cells in the brain and the rest of the nervous system.
"Those are the same types of receptors you activate if you smoke a cigarette," he says, explaining that nicotine in cigarette smoke "binds" to the receptor to trigger the release of a neurotransmitter, which is a chemical that carries a nerve impulse from one nerve cell to another, allowing nerve cells to communicate.
"Nicotine acts on those receptors in our brain, but they are in our brain for better reasons than to enjoy a cigarette," McIntosh says. Different forms or subtypes of nicotinic receptors control the release of different neurotransmitters. "That's important because if you had compounds to facilitate the release of one neurotransmitter and not another neurotransmitter, that opens up medicinal potential," he says.
"For instance, one receptor modifies the release of dopamine. There are inadequate amounts of dopamine in Parkinson's disease," so a medicine designed to fit into a certain subtype of nicotinic receptor would produce more dopamine and thus protect against the development of tremors and other Parkinson's symptoms. Indeed, other studies have found that smoking seems to forestall Parkinson's disease.
A medicine that could block certain nicotinic receptors could be used to help people stop smoking cigarettes, and the same method might work for alcoholism because nicotinic receptors may be involved in alcohol addiction, McIntosh says.
Other nicotinic receptors trigger the release of neurotransmitters involved in memory, so activating the right receptors might lessen Alzheimer's memory loss.
"One reason people smoke is they feel their thinking may be a little better, with increased attention and focus," McIntosh says, noting that pharmaceutical companies "would like to mimic that positive benefit without all the downsides of cigarette smoke."
Other nicotinic receptors influence "the release of serotonin and norepinephrine, two neurotransmitters strongly implicated in mood disorders" such as depression, so a drug to activate those receptors might treat depression, he adds.
Schizophrenics tend to smoke heavily because something in cigarette smoke "seems to help them filter out irrelevant stimuli. They can focus better," McIntosh says. So a drug aimed at certain nicotinic receptors might treat schizophrenia.
New Neurotoxin is a Key for Designing New Medicines
McIntosh says the new toxin itself is unlikely to become a drug because it blocks rather than stimulates nicotinic receptors. But because it can act on some types of nicotinic receptors and not others - like a key that opens some locks but not others - it has great potential as a tool for precisely identifying the shape and structure of the receptor "locks," thus making it easier to design new medicines or "keys" to fit those receptors and trigger them to release desired neurotransmitters.
In the new study, about 70 compounds from numerous cone snail species were screened in collaboration with Taylor's lab at the University of California, San Diego.
Taylor uses "acetylcholine binding protein" as a model for nicotinic receptors. In other words, cone snail toxin "keys" that fit into nicotinic receptor "locks" also fit into highly similar "locks" made of this binding protein. So the binding protein was used as a way to find toxins that also would fit into nicotinic receptors. The new OmIA toxin was most interesting because it tightly fits some nicotinic receptors but not others. A drug that tightly fits desired receptors but not others is less likely to have undesirable side effects.
Unlike nicotinic receptors, the binding protein can be grown in crystal form, allowing Taylor's team to use X-ray crystallography to make detailed microscopic pictures of how the toxin fit into the binding protein. Meanwhile, Han in South Korea used nuclear magnetic resonance to make pictures showing the structure of the new toxin.
Together, the images provide a highly detailed picture of how the cone snail toxin fits into the binding protein, and thus how it also would fit into a nicotinic receptor.
"By putting the two together, you can get a high-resolution picture of the binding site," says McIntosh. "That allows for rational drug development. It allows you to design compounds that will bind to the same [nicotinic receptor] site, and it allows you to begin to understand how to bind to one receptor subtype and not another" to trigger the release of whatever neurotransmitter is needed to treat or prevent a particular disease.
"It is the picture of the binding site and the ability to distinguish one type of nicotinic receptor from another that makes the toxin so valuable," he adds.
How the Study was Performed
The snails from which the new toxin was obtained were collected by divers in Olivera's native Philippines. Venomous snails use a dart-like tooth to zap fish, snails and other prey, injecting them with an immobilizing toxin. Venom from the collected snails was extracted at a lab in the Philippines, and then sent to Utah.
Once the screening process identified OmIA as promising, McIntosh and colleagues purified the toxin - one of perhaps 200 components in Conus omaria venom. They determined its chemical structure and then synthesized more of the toxin, since they had only a small amount of the natural version.
Next, the synthetic toxin was tested to see how well it acted as a "key" to fit into the "locks" represented both by binding proteins (from freshwater snails and a sea slug) and by actual nicotinic receptors, which came from rat cells but were grown in frog eggs. That allowed the researcher to grow various subtypes of the nicotinic receptors and see how well the toxin fit them.
Taylor and Han provided pictures of the physical structures of the binding protein "locks" and toxin "key," and then "used computer simulation to dock the two structures together," says McIntosh. "That generates a picture of the binding site - the points of contact between the toxin and the binding protein."
The site is the place a new drug would be designed to fit.
"The whole idea is to make the model of the nicotinic receptor so predictive that you can then really speed up the development of drugs," McIntosh says. "If you have an accurate model of the receptor, you can plug in a model of your drugs and do a lot of 'virtual screening.' Rather than synthesizing a million compounds and having all but one be duds, you can synthesize a few thousand compounds based on the model and come up with a better drug with less time and resources."
University of Utah
McIntosh is the same University of Utah researcher who - as an incoming freshman student in 1979 - discovered another "conotoxin" that was developed into Prialt, a drug injected into fluid surrounding the spinal cord to treat severe pain due to cancer, AIDS, injury, failed back surgery and certain nervous system disorders. Prialt was approved in late 2004 in the United States and was introduced in Europe last month.
Prialt, sold by Ireland's Elan Pharmaceuticals, took roughly 25 years to reach market after its discovery in venom from the fish-eating cone snail Conus magus or magician's cone. McIntosh says he expects it will take 10 to 20 years to develop new medications based on what is learned from the new toxin - named alpha conotoxin OmIA (oh-em-one-ay) - isolated from a cone snail species named Conus omaria, which lives in the Pacific and Indian oceans and eats other snails. It ranges from 1¾ to 3½ inches long.
McIntosh discovered and analyzed the new toxin with help from University of Utah cone snail research pioneer Baldomero "Toto" Olivera, who is a distinguished professor of biology, and lab technicians Sean B. Christensen and Cheryl Dowell.
Other coauthors of the study are Palmer Taylor, professor and dean of pharmacology at the University of California, San Diego, and his associates - Todd Talley, Igor Tsigelny and Kwok-Yiu Ho - as well as Kyou-Hoon Han at the Korea Research Institute of Bioscience and Biotechnology.
Diseases that Might Benefit from the New Snail Toxin
McIntosh says the OmIA toxin will be useful in designing new medicines because it fits like a key into certain lock-like "nicotinic acetylcholine receptors" found on nerve cells in the brain and the rest of the nervous system.
"Those are the same types of receptors you activate if you smoke a cigarette," he says, explaining that nicotine in cigarette smoke "binds" to the receptor to trigger the release of a neurotransmitter, which is a chemical that carries a nerve impulse from one nerve cell to another, allowing nerve cells to communicate.
"Nicotine acts on those receptors in our brain, but they are in our brain for better reasons than to enjoy a cigarette," McIntosh says. Different forms or subtypes of nicotinic receptors control the release of different neurotransmitters. "That's important because if you had compounds to facilitate the release of one neurotransmitter and not another neurotransmitter, that opens up medicinal potential," he says.
"For instance, one receptor modifies the release of dopamine. There are inadequate amounts of dopamine in Parkinson's disease," so a medicine designed to fit into a certain subtype of nicotinic receptor would produce more dopamine and thus protect against the development of tremors and other Parkinson's symptoms. Indeed, other studies have found that smoking seems to forestall Parkinson's disease.
A medicine that could block certain nicotinic receptors could be used to help people stop smoking cigarettes, and the same method might work for alcoholism because nicotinic receptors may be involved in alcohol addiction, McIntosh says.
Other nicotinic receptors trigger the release of neurotransmitters involved in memory, so activating the right receptors might lessen Alzheimer's memory loss.
"One reason people smoke is they feel their thinking may be a little better, with increased attention and focus," McIntosh says, noting that pharmaceutical companies "would like to mimic that positive benefit without all the downsides of cigarette smoke."
Other nicotinic receptors influence "the release of serotonin and norepinephrine, two neurotransmitters strongly implicated in mood disorders" such as depression, so a drug to activate those receptors might treat depression, he adds.
Schizophrenics tend to smoke heavily because something in cigarette smoke "seems to help them filter out irrelevant stimuli. They can focus better," McIntosh says. So a drug aimed at certain nicotinic receptors might treat schizophrenia.
New Neurotoxin is a Key for Designing New Medicines
McIntosh says the new toxin itself is unlikely to become a drug because it blocks rather than stimulates nicotinic receptors. But because it can act on some types of nicotinic receptors and not others - like a key that opens some locks but not others - it has great potential as a tool for precisely identifying the shape and structure of the receptor "locks," thus making it easier to design new medicines or "keys" to fit those receptors and trigger them to release desired neurotransmitters.
In the new study, about 70 compounds from numerous cone snail species were screened in collaboration with Taylor's lab at the University of California, San Diego.
Taylor uses "acetylcholine binding protein" as a model for nicotinic receptors. In other words, cone snail toxin "keys" that fit into nicotinic receptor "locks" also fit into highly similar "locks" made of this binding protein. So the binding protein was used as a way to find toxins that also would fit into nicotinic receptors. The new OmIA toxin was most interesting because it tightly fits some nicotinic receptors but not others. A drug that tightly fits desired receptors but not others is less likely to have undesirable side effects.
Unlike nicotinic receptors, the binding protein can be grown in crystal form, allowing Taylor's team to use X-ray crystallography to make detailed microscopic pictures of how the toxin fit into the binding protein. Meanwhile, Han in South Korea used nuclear magnetic resonance to make pictures showing the structure of the new toxin.
Together, the images provide a highly detailed picture of how the cone snail toxin fits into the binding protein, and thus how it also would fit into a nicotinic receptor.
"By putting the two together, you can get a high-resolution picture of the binding site," says McIntosh. "That allows for rational drug development. It allows you to design compounds that will bind to the same [nicotinic receptor] site, and it allows you to begin to understand how to bind to one receptor subtype and not another" to trigger the release of whatever neurotransmitter is needed to treat or prevent a particular disease.
"It is the picture of the binding site and the ability to distinguish one type of nicotinic receptor from another that makes the toxin so valuable," he adds.
How the Study was Performed
The snails from which the new toxin was obtained were collected by divers in Olivera's native Philippines. Venomous snails use a dart-like tooth to zap fish, snails and other prey, injecting them with an immobilizing toxin. Venom from the collected snails was extracted at a lab in the Philippines, and then sent to Utah.
Once the screening process identified OmIA as promising, McIntosh and colleagues purified the toxin - one of perhaps 200 components in Conus omaria venom. They determined its chemical structure and then synthesized more of the toxin, since they had only a small amount of the natural version.
Next, the synthetic toxin was tested to see how well it acted as a "key" to fit into the "locks" represented both by binding proteins (from freshwater snails and a sea slug) and by actual nicotinic receptors, which came from rat cells but were grown in frog eggs. That allowed the researcher to grow various subtypes of the nicotinic receptors and see how well the toxin fit them.
Taylor and Han provided pictures of the physical structures of the binding protein "locks" and toxin "key," and then "used computer simulation to dock the two structures together," says McIntosh. "That generates a picture of the binding site - the points of contact between the toxin and the binding protein."
The site is the place a new drug would be designed to fit.
"The whole idea is to make the model of the nicotinic receptor so predictive that you can then really speed up the development of drugs," McIntosh says. "If you have an accurate model of the receptor, you can plug in a model of your drugs and do a lot of 'virtual screening.' Rather than synthesizing a million compounds and having all but one be duds, you can synthesize a few thousand compounds based on the model and come up with a better drug with less time and resources."
University of Utah
Brain Disease Current Events and Brain Disease News RSSMember of NFL Hall of Fame diagnosed with degenerative brain disease
The Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine (BUSM) announced today that a recently deceased member of the NFL Hall of Fame suffered from the degenerative brain disease Chronic Traumatic Encephalopathy (CTE) when he died, becoming the 10th former NFL player diagnosed with the disease.
First former college football player diagnosed with CTE
The Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine (BUSM) announced today that a deceased former college football player who died at age 42 was already suffering from the degenerative brain disease, Chronic Traumatic Encephalopathy (CTE).
Healthy older brains not significantly smaller than younger brains, new imaging study shows
The belief that healthy older brains are substantially smaller than younger brains may stem from studies that did not screen out people whose undetected, slowly developing brain disease was killing off cells in key areas, according to new research. As a result, previous findings may have overestimated atrophy and underestimated normal size for the older brain.
Study shows how to boost value of Alzheimer's-fighting compounds
The polyphenols found in red wine are thought to help prevent Alzheimer's disease, and new research from Purdue University and Mount Sinai School of Medicine has shown that some of those compounds in fact reach the brain.
Sticky protein helps reinforce fragile muscle membranes
A new study by scientists at the University of Iowa shows why muscle membranes don't rupture when healthy people exercise.
Popular cancer drug linked to often fatal brain virus
The 57-year-old lawyer in New York had handily completed the New York Times' Saturday crossword puzzle - the hardest of the week - for years. But one Saturday morning, suddenly he couldn't retrieve the words to fill in the squares.
Study makes first connection between heart disorder and Alzheimer's disease
Researchers at Intermountain Medical Center in Salt Lake City believe that they have made a breakthrough connection between atrial fibrillation, a fairly common heart rhythm disorder, and Alzheimer's disease, the leading form of dementia among Americans.
New evidence ties gene to Alzheimer's
Of dozens of candidates potentially involved in increasing a person's risk for the most common type of Alzheimer's disease that affects more than 5 million Americans over the age of 65, one gene that keeps grabbing Johns Hopkins researchers' attention makes a protein called neuroglobin.
Topical Cream Studied as Way to Treat Skin Cancer without the Knife
In a case study of a type of melanoma skin cancer typically found on chronically sun-exposed skin, Saint Louis University researchers found that imiquimod, a topical cream, produced good results for patients when used together with surgery to treat the cancer, potentially helping doctors cut less.
Center for the Study of Traumatic Encephalopathy announces new findings
Leading medical experts at the Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine (BUSM) reported today that nine-year NFL veteran, former Tampa Bay Buccaneer Tom McHale was suffering from chronic traumatic encephalopathy (CTE), a degenerative brain disease caused by head trauma, when he died in 2008 at the age of 45.
More Brain Disease Current Events and Brain Disease News Articles
 |
Making the Connection Between Brain and Behavior: Coping with Parkinson's Disease by M.D. Joseph H. Friedman (Author) While patients and families are aware of the physical challenges that accompany Parkinson’s disease, few are prepared for the common behavioral issues that impact their quality of life, including depression, anxiety, dementia, paranoid delusions, and sleep disorders. This book, the only one of its kind, focuses entirely on an area that most doctors overlook. Written in layman’s terms, it helps readers understand and cope with a wide variety of Parkinson’s-related behavioral issues and offers guidance on communicating with the healthcare team. |
 |
Charlie Rose Science Series: From Potential of the Mind to Diseases of the Brain (December 20, 2007) Charlie Rose Science Series: From Potential of the Mind to Diseases of the Brain with Paul Nurse of Rockefeller University, Eric Kandel of Columbia University, Catherine Lord from the University of Michigan, Helen Mayberg of Emory University and Donald Price of Johns Hopkins University. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
Life With a Battery-Operated Brain - A Patient's Guide to Deep Brain Stimulation Surgery for Parkinson's Disease by Jackie Hunt Christensen (Author) Why would anyone say ''Let's stick wires into someone's brain, run voltage through it, and see what happens!'' So asks Jackie Hunt Christensen in Life With a Battery-Operated Brain: A Patient's Guide to Deep Brain Stimulation Surgery for Parkinson s Disease. Author Christensen answers this question -- and more -- in her unique and comprehensive book, as she has first-hand knowledge of the procedure commonly referred to as DBS. She herself lived with Parkinson's disease for more than seven years before electing to be evaluated for DBS surgery. It was not a fast and easy choice. For Christensen, a fear of DBS surgery -- which involves placing one or two electrical wires inside the brain -- and its potential complications had to be weighed against quality of life without the surgery, a... |
 |
Native Remedies Triple Complex Brain Tonic and StudyPlus ComboPack by Native Remedies The ComboPack of Brain Tonic and StudyPlus consists of multiple remedies that work well together to provide increased support for your condition. This ComboPack assists with improved focus, memory and concentration with added brain tonic for maximum results. The Brain Tonic improves concentration, memory and balanced mood while the StudyPlus is used to help focus attention during study sessions. |
|
Mavericks, Miracles & Medicine (Set of 2 VHS Tapes) Vol. 1 The Heart/transplants Vol. 2 The Brain/infectious Disease A & E Videos capture the glory, tragedy, and drama of human experience. Brilliant specials, astounding documentaries, and vibrant dramatizations bring the past home to you. | |
 |
Hearts&Minds No-Stir Peanut Butter with Olive Oil and Omega-3Crunchy, 11.3 Ounce Bottles (Pack of 6) by Hearts&Minds Hearts&Minds LLC creates great tasting products thoughtfully made with the consumer's heart in mind by using heart healthy olive oil and omega-3 (EPA/DHA) to replace a portion of the fat in foods consumers love. Hearts&Minds® peanut butter helps con |
 |
Transfusion/Brain Disease Organ Failure (Primary Contributor) |
|
Dizzy Brain of Mrs. Bliss by Beautiful Disease | |
 |
New Science of Alzheimer's Disease / TIME Cover: July 17, 2000, Art Poster by TIME Magazine by barewalls The most eagerly awaited event in the editorial cycle at TIME Magazine is always the selection of the cover. The best covers capture the zeitgeist of the week while surviving the judgment of history. As browsing this collection of TIME cover art prints shows, TIME is as good a record as any of who and what mattered over the past 80-plus years. And so when TIME captures a person, an event or a trend within its iconic red borders, the magazine is adding that extra dose of significance that no other publication can quite match. That is one reason why the original artwork for more than 800 TIME covers now resides in the National Portrait Gallery in Washington. Thanks to an amazing roster of artists, photographers and graphic designers, from TIME's earliest charcoal drawings of cover subjects... |
 |
The Better Brain Book by David Perlmutter (Author), Carol Colman (Author) Loss of memory is not a natural part of aging-and this book explains why. Celebrated neurologist David Perlmutter reveals how everyday memory-loss-misplacing car keys, forgetting a name, losing concentration in meetings-is actually a warning sign of a distressed brain. Here he offers a simple plan for repairing those problems, and regaining and maintaining clarity by offering the tools for: Building a better brain through nutrition, lifestyle changes, and brain workouts Coping with specific brain disorders such as stroke, vascular dementia, Alzheimer's, Parkinson's, multiple sclerosis, and Lou Gehrig's disease Understanding risk factors and individually tailoring a diet and supplementary program Features a "Life Style Audit," quizzes, brain... |
| © 2009 BrightSurf.com |